Anemia Market Growth Fueled by FDA Approvals, Improved Screening, and Expanding Healthcare Infrastructure, finds DelveInsight | GSK, MegaPro Biomedical, Agios Pharmaceuticals, Nemysis

The anemia market is projected to experience significant growth across the seven major markets (7MM). This growth is driven by several factors, including increased disease awareness, improved screening practices, and expanding healthcare infrastructure dedicated to managing anemia. Key companies such as GSK, MegaPro Biomedical, Agios Pharmaceuticals, and Nemysis are leading the charge in innovation within this landscape.

DelveInsight's latest report, "Anemia - Market Insight, Epidemiology and Market Forecast - 2032," combines robust epidemiological data with insights into anemia market trends, competitive landscape analysis, and assessments of the patient journey. The report forecasts that the market for anemia in the 7MM, which include the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, is expected to expand positively with a decent CAGR by 2032. This expansion is primarily attributed to increased disease awareness, enhanced screening practices, and improved healthcare infrastructure dedicated to anemia management.

Download the Anemia market report to understand which factors are driving the iron deficiency anemia treatment market @ https://www.delveinsight.com/sample-request/anemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Anemia presents through symptoms such as fatigue, weakness, dizziness, headaches, pale skin, rapid heartbeat, and shortness of breath. Nutritional deficiencies, particularly iron deficiency, are the most common causes, but folate, vitamin B12, and A deficiencies also contribute significantly. Other causes include hemoglobinopathies and infectious diseases like malaria, tuberculosis, HIV, and parasitic infections.

According to DelveInsight's report, anemia remains a significant global health concern, particularly affecting women of reproductive age. The report estimates that approximately 43% of children, 38% of pregnant women, and 29% of non-pregnant women are affected by anemia. Additionally, around 30% of all women of reproductive age have anemia, indicating that iron deficiency anemia predominantly impacts women compared to men and is more prevalent during pregnancy. The study also shows a decline in dietary iron intake of about 6.6% in males and 9.5% in females in the U.S. between 1999 and 2018.

Gain valuable insights into Anemia prevalence and patient demographics across the 7MM @ https://www.delveinsight.com/sample-request/anemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Current treatment protocols depend on the underlying causes of anemia. For iron-deficiency anemia, treatment typically involves iron supplements and dietary adjustments. Anemia due to vitamin deficiencies requires B12 or folate supplementation, while anemia related to chronic disease often necessitates erythropoiesis-stimulating agents. Diagnosis is primarily based on blood tests that measure hemoglobin levels, hematocrit, and red blood cell counts.

In the US, several medications are approved to treat anemia, including iron supplements like ferrous sulfate and iron dextran (INFeD), as well as erythropoiesis-stimulating agents (ESAs) like epoetin alfa (EPOGEN, PROCRIT) and darbepoetin alfa (ARANESP). Notably, in February 2023, JESDUVROQ (GSK) became the first oral treatment approved for anemia caused by chronic kidney disease in adults.

DelveInsight's analysis indicates that the therapeutic landscape for anemia is undergoing significant innovation, with several promising candidates in the development pipeline. Drugs such as IHAT-02/IDAX (Nemysis), AG-946 (Agios Pharmaceuticals) and MPB-1514/ IOP Injection (MegaPro Biomedical), among others are expected to enter the market during the forecast period, potentially impacting the trajectory of the anemia therapeutic market.

Recently, AG-946 (Agios Pharmaceuticals), an oral pyruvate kinase activator, demonstrated promising results in improving anemia during its phase II study.

The emergence of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) signifies a paradigm shift in treatment approaches. These oral medications offer potential advantages over traditional injectable therapies, including more consistent hemoglobin levels, improved iron utilization, and enhanced patient compliance.

Stay ahead with the latest breakthroughs, FDA approvals, and eco-friendly innovations shaping the future of the iron deficiency anemia treatment landscape. Visit https://www.delveinsight.com/sample-request/anemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

In conclusion, the anemia treatment market is positioned for significant growth, driven by innovative therapeutic approaches and greater awareness of this widespread condition. Oral alternatives to injectable therapies are transforming patient care, particularly for individuals with chronic kidney disease and rare blood disorders. As research advances and new therapies receive approval, patients with iron deficiency anemia, transfusion-dependent anemia, and other forms of this condition can anticipate improved outcomes and quality of life.

Scope of the Anemia Market Report

Study Period: 2020-2032
Coverage: 7MM [The United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Key Anemia Companies
Key Anemia Therapies
Anemia Therapeutic Assessment: Anemia current marketed and Anemia emerging therapies
Anemia Market Dynamics: Anemia market drivers and Anemia market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Anemia Unmet Needs, KOL's views, Analyst's views, Anemia Market Access and Reimbursement

Table of contents
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Anemia Market Overview at a Glance
5. Epidemiology and Market Forecast Methodology
6. Key Events
7. Anemia Background and Overview
8. Anemia Treatment
9. Anemia Epidemiology and Patient Population in the 7MM
10. Anemia Patient Journey
11. Anemia Marketed Drug
12. Anemia Emerging Drugs
13. Anemia: 7MM Analysis
14. Unmet needs
15. SWOT Analysis
16. KOL Views
17. Market Access and Reimbursement
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

This release was published on openPR.